不同剂量阿托伐他汀对行PCI术患者血脂和C反应蛋白的影响

Influences of High and Low Dose Atorvastatin on Lipids and C-reactive Protein of Patients Post PCI

目的:探讨急性冠脉综合症(ACS)行经皮冠状动脉支架植入术(PCI)患者应用不同剂量阿托伐他汀后对血脂和C反应蛋白(CRP)的影响。方法:选择96例接受PCI术治疗的ACS患者,随机平均分为A组和B组,在常规药物治疗基础上,A组(48例)给予80 mg阿托伐他汀口服,B组(48例)给予20 mg阿托伐他汀口服,检测术前1天和术后1周两组患者的血脂和CRP水平,并进行统计分析。结果:术后1周,两组患者血脂水平较术前1天均有明显改善,但A组改善更明显,统计学有显著性差异(P<0.05)。术后1周,两组患者血清CRP水平较术前1天均明显降低,但A组降低更明显,统计学有显著性差异(P<0.05)。结论:对接受PCI治疗的ACS患者给予大剂量阿托伐他汀治疗,能显著改善血脂水平,降低血清CRP水平,有利于减少远期心脑血管事件的发生。

Objective： To investigate influences of different doses of atorvastatin on lipids and C-reactive protein （CRP） of the acute coronary syndrome （ACS） patients undergoing percutaneous coronary artery stent implantation （PCI）. Methods： 96 ACS patients with PCI treatment were randomly divided into group A and group B. On the basis of conventional drug treatment, the group A （48 cases） was given 80 mg atorvastatin, while the group B （48 cases） was given 20 mg atorvastatin. The lipids and CRP levels of the two groups one day before PCI and one week after the procedure were tested and analyzed. Results： After one week of treatment, the lipids levels of the two groups were obviously improved, however, the level of the group A was improved more apparently compared with that of the group B （P〈0.05） in one week after discharge. Compared with one day before operation, the CRP levels of the two groups were obviously reduced with statistical difference P〈0.05. The CRP level of the group A was reduced more than that of group B （P〈0.05）. Conclusion： High dose of atorvastatin in ACS patients post PCI can evidently improve the lipids level, reduce the CRP level. It could reduce the occurrence of heart and cerebral vessels disease.